BENSON HILL INC (BHIL)

US0824902029 - Common Stock

1.81  +0.03 (+1.69%)

Fundamental Rating

2

BHIL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 92 industry peers in the Food Products industry. BHIL may be in some trouble as it scores bad on both profitability and health. BHIL is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

BHIL had negative earnings in the past year.
BHIL had a negative operating cash flow in the past year.
BHIL had negative earnings in each of the past 5 years.
BHIL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of BHIL (-73.99%) is worse than 93.02% of its industry peers.
BHIL has a Return On Equity of -379.14%. This is amonst the worse of the industry: BHIL underperforms 91.86% of its industry peers.
Industry RankSector Rank
ROA -73.99%
ROE -379.14%
ROIC N/A
ROA(3y)-30.36%
ROA(5y)-33.1%
ROE(3y)-83.39%
ROE(5y)-77.15%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BHIL has a worse Gross Margin (5.33%) than 81.40% of its industry peers.
In the last couple of years the Gross Margin of BHIL has declined.
BHIL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.76%
GM growth 5Y-43.1%

More info and screens

3

2. Health

2.1 Basic Checks

BHIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
BHIL has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, BHIL has a worse debt to assets ratio.

2.2 Solvency

BHIL has an Altman-Z score of -6.09. This is a bad value and indicates that BHIL is not financially healthy and even has some risk of bankruptcy.
BHIL has a Altman-Z score of -6.09. This is amonst the worse of the industry: BHIL underperforms 89.53% of its industry peers.
BHIL has a Debt/Equity ratio of 3.12. This is a high value indicating a heavy dependency on external financing.
BHIL's Debt to Equity ratio of 3.12 is on the low side compared to the rest of the industry. BHIL is outperformed by 91.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Altman-Z -6.09
ROIC/WACCN/A
WACC9.72%

2.3 Liquidity

BHIL has a Current Ratio of 2.21. This indicates that BHIL is financially healthy and has no problem in meeting its short term obligations.
BHIL has a Current ratio of 2.21. This is in the better half of the industry: BHIL outperforms 68.60% of its industry peers.
BHIL has a Quick Ratio of 1.74. This is a normal value and indicates that BHIL is financially healthy and should not expect problems in meeting its short term obligations.
BHIL has a better Quick ratio (1.74) than 81.40% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 1.74

More info and screens

4

3. Growth

3.1 Past

BHIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.20%, which is quite good.
Looking at the last year, BHIL shows a very negative growth in Revenue. The Revenue has decreased by -49.19% in the last year.
BHIL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 156.06% yearly.
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
Revenue 1Y (TTM)-49.19%
Revenue growth 3Y100.08%
Revenue growth 5Y156.06%
Sales Q2Q%-69.84%

3.2 Future

BHIL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.04% yearly.
The Revenue is expected to decrease by -33.44% on average over the next years. This is quite bad
EPS Next Y40.84%
EPS Next 2Y34.39%
EPS Next 3Y23.04%
EPS Next 5YN/A
Revenue Next Year-71.85%
Revenue Next 2Y-52.14%
Revenue Next 3Y-33.44%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHIL. In the last year negative earnings were reported.
Also next year BHIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BHIL's earnings are expected to grow with 23.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.39%
EPS Next 3Y23.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BHIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BENSON HILL INC

NASDAQ:BHIL (1/15/2025, 11:33:10 AM)

1.81

+0.03 (+1.69%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners22.13%
Inst Owner Change-0.02%
Ins Owners8.8%
Ins Owner Change-0.03%
Market Cap11.06M
Analysts43.33
Price TargetN/A
Short Float %1.82%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-48.82%
Min EPS beat(2)-67.13%
Max EPS beat(2)-30.51%
EPS beat(4)1
Avg EPS beat(4)-40.73%
Min EPS beat(4)-67.24%
Max EPS beat(4)1.96%
EPS beat(8)3
Avg EPS beat(8)-18.22%
EPS beat(12)6
Avg EPS beat(12)-8.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)10.88%
Min Revenue beat(2)-14.5%
Max Revenue beat(2)36.26%
Revenue beat(4)2
Avg Revenue beat(4)6.8%
Min Revenue beat(4)-25.47%
Max Revenue beat(4)36.26%
Revenue beat(8)5
Avg Revenue beat(8)7.9%
Revenue beat(12)7
Avg Revenue beat(12)-2.44%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5633.33%
EPS NY rev (1m)-15.43%
EPS NY rev (3m)-15.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-3.92%
Revenue NY rev (3m)-3.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-21.02
EYN/A
EPS(NY)-4.75
Fwd EYN/A
FCF(TTM)-6.91
FCFYN/A
OCF(TTM)-6.55
OCFYN/A
SpS33.65
BVpS4.39
TBVpS3.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.99%
ROE -379.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.33%
FCFM N/A
ROA(3y)-30.36%
ROA(5y)-33.1%
ROE(3y)-83.39%
ROE(5y)-77.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.76%
GM growth 5Y-43.1%
F-Score3
Asset Turnover1.49
Health
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.42%
Cap/Sales 1.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 1.74
Altman-Z -6.09
F-Score3
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)124.08%
Cap/Depr(5y)136.84%
Cap/Sales(3y)13.82%
Cap/Sales(5y)13.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
EPS Next Y40.84%
EPS Next 2Y34.39%
EPS Next 3Y23.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-49.19%
Revenue growth 3Y100.08%
Revenue growth 5Y156.06%
Sales Q2Q%-69.84%
Revenue Next Year-71.85%
Revenue Next 2Y-52.14%
Revenue Next 3Y-33.44%
Revenue Next 5YN/A
EBIT growth 1Y11.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.41%
EBIT Next 3Y24.07%
EBIT Next 5YN/A
FCF growth 1Y66.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.14%
OCF growth 3YN/A
OCF growth 5YN/A